原位黑色素瘤诊断后的死亡风险
该基于人群的队列研究纳入2000-2018年美国SEER数据库137 872例首次原发性原位黑色素瘤(MIS)成人患者,评估诊断后15年黑色素瘤特异性生存率为98.4%(95%CI 98.3%-98.5%),15年相对生存率为112.4%(95%CI 112.0%-112.8%)。黑色素瘤特异性SMR为1.89(95%CI 1.77-2.02),全因SMR为0.68(95%CI 0.67-0.7)。高龄(≥80岁)和肢端雀斑样组织学与黑色素瘤特异性死亡风险升高相关,继发原发性浸润性黑色素瘤亦增加死亡风险。
要点
- MIS患者15年黑色素瘤特异性生存率98.4%,相对生存率112.4%。
- 黑色素瘤特异性SMR 1.89,全因SMR 0.68。
- 高龄(≥80岁)和肢端雀斑样组织学与黑色素瘤特异性死亡风险升高相关。
核心结论
- MIS诊断后黑色素瘤特异性死亡风险增加但绝对值低,且患者比一般人群活得更长,提示在寻求医疗保健的人群中发现了大量低风险疾病。
研究设计与样本
- 基于美国SEER项目的基于人群的队列研究,纳入2000-2018年首次原发性MIS成人患者137 872例,分析时间为2022年7月至9月。
主要发现
- 15年黑色素瘤特异性生存率为98.4%(95%CI 98.3%-98.5%),15年相对生存率为112.4%(95%CI 112.0%-112.8%)。
- 黑色素瘤特异性SMR为1.89(95%CI 1.77-2.02),全因SMR为0.68(95%CI 0.67-0.7)。
- 80岁及以上患者黑色素瘤特异性死亡风险为7.4%,60-69岁患者为1.4%,调整后HR为8.2(95%CI 6.7-10.0)。
- 肢端雀斑样组织学患者黑色素瘤特异性死亡风险为3.3%,浅表扩散型患者为0.9%,HR为5.3(95%CI 2.3-12.3)。
- 6751例(4.3%)发生第二原发性浸润性黑色素瘤,11 628例(7.4%)发生第二原发性MIS;与无后续黑色素瘤的患者相比,第二原发性浸润性黑色素瘤患者黑色素瘤特异性死亡风险调整后HR为4.1(95%CI 3.6-4.6),第二原发性MIS患者调整后HR为0.7(95%CI 0.6-0.9)。
临床怎么用
- 对于MIS患者,尤其是高龄(≥80岁)或肢端雀斑样组织学患者,应关注黑色素瘤特异性死亡风险。
- 诊断MIS后发生第二原发性浸润性黑色素瘤与黑色素瘤特异性死亡风险升高相关。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The incidence of melanoma in situ (MIS) is increasing more rapidly than any invasive or in situ cancer in the US. Although more than half of melanomas diagnosed are MIS, information about long-term prognosis following a diagnosis of MIS remains unknown. OBJECTIVE: To evaluate mortality and factors associated with mortality after a diagnosis of MIS. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study of adults with a diagnosis of first primary MIS from 2000 to 2018 included data from the US Surveillance, Epidemiology, and End Results Program, which were analyzed from July to September 2022. MAIN OUTCOMES AND MEASURES: Mortality after a diagnosis of MIS was evaluated using 15-year melanoma-specific survival, 15-year relative survival (ie, compared with similar individuals without MIS), and standardized mortality ratios (SMRs). Cox regression was used to estimate hazard ratios (HRs) for death by demographic and clinical characteristics. RESULTS: Among 137 872 patients with a first-and-only MIS, the mean (SD) age at diagnosis was 61.9 (16.5) years (64 027 women [46.4%]; 239 [0.2%] American Indian or Alaska Native, 606 [0.4%] Asian, 344 [0.2%] Black, 3348 [2.4%] Hispanic, and 133 335 [96.7%] White individuals). Mean (range) follow-up was 6.6 (0-18.9) years. The 15-year melanoma-specific survival was 98.4% (95% CI, 98.3%-98.5%), whereas the 15-year relative survival was 112.4% (95% CI, 112.0%-112.8%). The melanoma-specific SMR was 1.89 (95% CI, 1.77-2.02); however, the all-cause SMR was 0.68 (95% CI, 0.67-0.7). Risk of melanoma-specific mortality was higher for older patients (7.4% for those 80 years or older vs 1.4% for those aged 60-69 years; adjusted HR, 8.2; 95% CI, 6.7-10.0) and patients with acral lentiginous histology results (3.3% for acral lentiginous vs 0.9% for superficial spreading; HR, 5.3; 95% CI, 2.3-12.3). Of patients with primary MIS, 6751 (4.3%) experienced a second primary invasive melanoma and 11 628 (7.4%) experienced a second primary MIS. Compared with patients without a subsequent melanoma, the risk of melanoma-specific mortality was increased for those with a second primary invasive melanoma (adjusted HR, 4.1; 95% CI, 3.6-4.6) and was decreased for those with a second primary MIS (adjusted HR, 0.7; 95% CI, 0.6-0.9). CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that patients with a diagnosis of MIS have an increased but low risk of melanoma-specific mortality and live longer than people in the general population, suggesting that there is significant detection of low-risk disease among health-seeking individuals. Factors associated with death following MIS include older age (≥80 years) and subsequent primary invasive melanoma.
引用
- Patel VR, Roberson ML, Pignone MP, et al. Risk of Mortality After a Diagnosis of Melanoma In Situ. JAMA Dermatol. 2023. PMID: 37285145. doi:10.1001/jamadermatol.2023.1494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。